ESTRO 2022 - Abstract Book

S1512

Abstract book

ESTRO 2022

A total of 5 prostate cancer (PC) patients treated at a 1.5T MR-Linac (20 x 3 Gy) were included into this retrospective study. Two different DDA strategies for online adaptive MRgRT were compared. First, retrospective (re) DDA was carried out, where all adaptive MRgRT fractions were deformably registered to the MRI of the first fraction (fx01). The second strategy consisted of a sequential (seq) DDA, applying deformable registration and subsequent dose warping of one data set to that of the previous fraction, e.g. fx03 to fx04. For automatic OAR contouring (MR deep learning model) based on T2w MRI and deformable image registration Monaco ADMIRE (Elekta) was used, whereas DDA and DS were realized via 3Dslicer (open source software). Clinically relevant dose criteria for PC (cf. table 1) were assessed for prostate, bladder, and rectum. The resulting dose distributions were compared to a fraction-based summation of these criteria mimicking the current MR-Linac workflow where no DDA is available. Results Table 1 summarizes the absolute differences between the dosimetric criterial obtained with the two different DDA strategies and a fraction-wise dose summation approach. Mean absolute differences between DS and reDDA for prostate D2%, D50% and D98% were 1.0 Gy, 0.0 Gy and -0.5 Gy, respectively. In contrast, differences of bladder D2%, V48Gy and V56Gy resulted in 3.1 Gy, 3.8% and 3.0%, as well as for rectum -0.1 Gy, 2.2% and 1.5%. The comparison of seqDDA and DS yielded mean absolute differences of D2 = 0.6 Gy, D50 = 0.1 Gy and D98 = -0.5 Gy, for bladder D2 = 0.1 Gy, V48 = 0.5% and V56 = 0.7%, and for rectum D2 = 0.5 Gy, V48 = 0.5% and V56 = 2.6%, respectively.

Conclusion In this study, we showed first results of two different DDA strategies for adaptive MRgRT of PC. Mean differences between fraction-wise DS and DDA approaches were only small, whereas, for individual patients, large differences were observed especially for maximum OAR dose tolerances which could result in a detrimental impact on quality of life. Furthermore, the two dose accumulation strategies show a variation compared to each other, especially in OAR. A further investigation with a larger number of patients is required before DDA strategies can be used in clinical practice to steer online adaptive MRgRT.

PO-1713 DVH based evaluation of dose accumulation in an adaptive MR-linac workflow

E. Fredén 1 , D. Tilly 2,3 , A. Ahnesjö 2

1 Södersjukhuset, Department of Oncology, Stockholm, Sweden; 2 Uppsala University, Medical Radiation Sciences; Department of Immunology, Genetics and Pathology, Uppsala, Sweden; 3 Elekta Instruments AB, -, Uppsala, Sweden Purpose or Objective Volume-at-dose (VaD) criteria are commonly used in treatment planning as dose-response surrogates for OARs. For exploration of adaptive workflows, it is important to investigate the robustness of VaD measures under different conditions. The first objective of this study was to investigate the variability of rectum VaD for prostate cancer patients (PCa) by simulating non-adaptive and adaptive treatment workflows (WFs). In an adaptive MR-linac WF, accumulated dose (from previous fractions) can potentially be used as input to plan adaptation; the fraction doses need to be accumulated to a common anatomy via dose mapping. The second objective was to study the effect of dose mapping on rectum VaD.